Suganthi Suppiah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suganthi Suppiah has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Azaibi Tamin
COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Brinda Kamalia
Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA
1 shared publication Charles Dusseau
United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States
1 shared publicationCharles Ogden
United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States
1 shared publication- Christine C. Lee
Enteric Diseases Laboratory Branch, Centers for Disease Control and Prevention
1 shared publication Cristen Young
Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States
1 shared publication
Latest Publications
- Open Access
- 3 August 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (9) , pgad256
Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus
Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.
- 3 August 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (9) , pgad256
Open AccessNucleoside analogs NM107 and AT-527 are antiviral against rubella virus
Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.